-
Jan 16, 2025 | 
cgtlive.com | Manali K. Kamdar |Noah Stansfield
This is the third part of an interview with Manali Kamdar, MD. For the first part, click here. For the second part, click here.
-
Jan 15, 2025 | 
cgtlive.com | Manali K. Kamdar |Noah Stansfield
This is the second part of an interview with Manali Kamdar, MD. For the first part, click here.
-
Jan 13, 2025 | 
cgtlive.com | Manali K. Kamdar |Noah Stansfield
This is the third part of an interview with Manali Kamdar, MD. For the second part, click here. For the first part, click here. “Please if you think of a [patient with] refractory, diffuse LBCL in the second line setting or third line setting, please refer them to a CAR-T academic center or a community site capable of doing CD19 CAR-T ASAP because it is really of the essence to get the patient to a CAR-T physician.
-
Jan 10, 2025 | 
cgtlive.com | Manali K. Kamdar |Noah Stansfield
This is the second part of an interview with Manali Kamdar, MD. For the first part, click here.
-
Oct 31, 2024 | 
onclive.com | Manali K. Kamdar
CommentaryVideoOctober 31, 2024Author(s):Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.
-
Aug 28, 2024 | 
onclive.com | Manali K. Kamdar
CommentaryVideoAugust 28, 2024Author(s):Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.
-
Jul 19, 2024 | 
cgtlive.com | Manali K. Kamdar
“Especially with follicular lymphoma, the response rates are just stellar. The median follow up is a little under 3 years right now, but at this point in time, the median duration of response and responders [are great]. Personally, for the people I enrolled on the trials, they're all in a complete remission, they've gone back to life, they have not relapsed. They're young patients and older patients across all age groups.
-
Jul 17, 2024 | 
cgtlive.com | Manali K. Kamdar
"We see, based on these subgroup analysis, that patients do really well, but for patients who are heavily treated with5 or more lines of prior treatment, I think, given that the liso-cel efficacy goes slightly lower, it's really important to keep bringing these constructs ahead in the algorithm for managing management of mantle cell lymphoma, because so far, it remains a fairly heterogeneous disease.
-
Jul 11, 2024 | 
cgtlive.com | Manali K. Kamdar
“I think experience is very important. I will say that academic centers, where I practice, we have a well-oiled machinery in terms of resources, staffing, in order to successfully take patients through CAR-T cell therapy, so the wariness around toxicities, finagling logistics, especially payer authorization, and all of that, I think we have ways to circumvent the delays. So, it's certainly very important to build around this experience with regards to the uptake of CAR T-cell therapy.
-
Jul 4, 2024 | 
cgtlive.com | Manali K. Kamdar
“We got to present the subgroup analysis of the Transcend-NHL-001 mantle cell lymphoma cohort study. This is a study that investigated lisocabtagene maraleucel in patients with relapsed refractory mantle cell lymphoma.
